Is Poly Medicure the Best Stock in Its Sector? A Look at the Numbers

Is Poly Medicure the best stock in its sector? The stock trades on the NSE at Rs 1,589 as of 15 October 2026, within its 52-week range of Rs 1,182.00 to Rs 2,094.30. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Poly Medicure

Poly Medicure Ltd, based in Faridabad, makes disposable medical devices. Its products include infusion sets, IV catheters, dialysis products and blood management devices, which it sells in India and in many export markets. At a market capitalisation of Rs 16,079 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Poly Medicure the Best Stock in Its Sector?

Poly Medicure makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Poly Medicure's 51.39x P/E is below the 61.23x Industry P/E and Concord Biotech at 52.96x, though above Laxmi Dental at 35.28x, while its 10.37% ROE is lower than Laxmi Dental at 13.74% and Concord Biotech at 12.94%, and its debt to equity ratio of 0.11 is above Laxmi Dental at 0.05 and Concord Biotech at 0.00.

Metric	Poly Medicure
CMP (NSE)	Rs 1,589.30
52-Week High / Low	Rs 2,094.30 / Rs 1,182.00
Market Cap	Rs 16,079 Cr
P/E (TTM) vs Industry P/E	51.39x vs 61.23x
P/B	5.18
ROE	10.37%
EPS (TTM)	Rs 30.87
Dividend Yield	0.22%
Debt to Equity	0.11

Compare Poly Medicure Against Other Healthcare Sector Stocks

How Poly Medicure Compares Against Its Healthcare Sector Peers

The table below sets Poly Medicure against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Poly Medicure	16,079	51.39	10.37%	0.11
Laxmi Dental	1,091	35.28	13.74%	0.05
Concord Biotech	14,449	52.96	12.94%	0.00
Peer average (2 companies)	-	44.12	13.34%	0.03

Measured against the peer averages, Poly Medicure's P/E is 16 percent above the 44.12x average, and its ROE is 2.97 percentage points below the 13.34% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Poly Medicure Worth Watching in Healthcare

• Scale: At Rs 16,079 Cr, its market capitalisation is larger than Laxmi Dental (Rs 1,091 Cr) and Concord Biotech (Rs 14,449 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Rising hospital capacity and growing exports of medical consumables drive volumes.
• Key risk: Its return on equity is modest for the multiple it trades on, and the peer set for listed medical device makers is thin, so comparisons should be read with care.

Poly Medicure Valuation: Is It Justified?

At a P/B ratio of 5.18, the market pays about Rs 5.18 for every rupee of book value, and the EPS (TTM) of Rs 30.87 is the earnings base behind the P/E. The stock trades about 24 percent below its 52-week high and about 34 percent above its 52-week low. The dividend yield of 0.22% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Poly Medicure and other Healthcare sector stocks.

How to Track Poly Medicure Before You Invest

Before deciding whether Poly Medicure deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Poly Medicure to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Poly Medicure gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Healthcare depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Poly Medicure the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Poly Medicure has a 10.37% ROE and trades at 51.39x P/E against a 61.23x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 13.34% peer average and its P/E is above the 44.12x peer average. Its debt to equity ratio of 0.11 is above the 0.03 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Poly Medicure?

Ans. Poly Medicure was trading at Rs 1,589.30 on the NSE as of 15 October 2026, and its 52-week range runs from Rs 1,182.00 to Rs 2,094.30. That leaves the share price 24 percent short of the 52-week high and 34 percent clear of the 52-week low. Its market capitalisation is Rs 16,079 Cr and its EPS (TTM) is Rs 30.87, which is the earnings figure behind the 51.39x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Poly Medicure belong to?

Ans. Poly Medicure is classified under the Healthcare sector on Univest, and that group of listed companies is the reference point for the 61.23x Industry P/E used in this article. The 2 named peers compared here are Laxmi Dental and Concord Biotech, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Healthcare sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Poly Medicure compare to its sector peers on P/E?

Ans. Poly Medicure's P/E of 51.39x is above the 44.12x average of the 2 named peers, with Laxmi Dental at 35.28x and Concord Biotech at 52.96x. It also sits below the 61.23x Industry P/E, which is the benchmark for the wider Healthcare sector. A P/E that is above a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 5.18 gives one more view of how the market values its book value.

What is Poly Medicure's return on equity?

Ans. Poly Medicure reported a return on equity of 10.37%, which is below the 13.34% average of its named peers, with Laxmi Dental at 13.74% and Concord Biotech at 12.94%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.11 against a peer average of 0.03. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Poly Medicure based on its sector position?

Ans. Sector position is only one input into an investment decision. Poly Medicure has a 10.37% ROE and a 51.39x P/E, which make it worth researching further, and its dividend yield is 0.22%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.